COVID-19合并急性(心)肌心包炎:62家西班牙急诊科病例对照多中心研究
该研究为病例对照、回顾性、连续纳入研究,在62家西班牙急诊科开展,比较COVID-19合并急性(心)肌心包炎患者(病例)与COVID-19无急性(心)肌心包炎患者(对照A)及非COVID急性(心)肌心包炎患者(对照B)的临床特征与结局。共识别67例COVID-19合并急性(心)肌心包炎,标化发病率56.5/10万/年,相对非COVID人群OR=4.43(95%CI 3.98–4.94)。病例胸痛更少、心电图改变更不典型、NT-proBNP更高、超声左右心室功能障碍更多、更需正性肌力/血管升压药;入ICU高于对照A(OR=3.22,95%CI 1.43–7.23),院内死亡高于对照B(OR=7.75,95%CI 2.77–21.7)。作者建议对COVID-19患者的急性(心)肌心包炎快速识别、超声评估心肌心包炎症/功能障碍,必要时使用血管活性药物。
要点
- COVID-19患者中急性(心)肌心包炎作为首发表现不常见(约1‰病例),但标化发病率56.5/10万/年,为非COVID人群的4倍以上(OR=4.43,95%CI 3.98–4.94)。
- COVID-19合并急性(心)肌心包炎患者胸痛更少、心电图改变更不典型,NT-proBNP更高,超声示左右心室功能障碍更多,更需正性肌力/血管升压药。
- COVID-19合并急性(心)肌心包炎患者入ICU率高于COVID-19无急性(心)肌心包炎患者(OR=3.22,95%CI 1.43–7.23)。
- COVID-19合并急性(心)肌心包炎患者院内死亡率高于非COVID急性(心)肌心包炎患者(OR=7.75,95%CI 2.77–21.7)。
- 作者建议对COVID-19患者的急性(心)肌心包炎快速识别、行超声心动图评估心肌心包炎症/功能障碍,必要时使用血管活性药物。
适用人群与场景
- 62家西班牙急诊科连续纳入的COVID-19合并急性(心)肌心包炎患者(病例),与COVID-19无急性(心)肌心包炎患者(对照A)及非COVID急性(心)肌心包炎患者(对照B)比较。
处置流程与药物剂量
- 作者建议:对COVID-19患者的急性(心)肌心包炎快速识别,行超声心动图评估心肌心包炎症/功能障碍,必要时使用血管活性药物。
研究设计与关键结果
- 研究类型:病例对照、回顾性、连续纳入、多中心(62家西班牙急诊科)。
- 共识别67例COVID-19合并急性(心)肌心包炎,标化发病率56.5/10万/年,相对非COVID人群OR=4.43(95%CI 3.98–4.94)。
- COVID-19病例胸痛较非COVID患者更少、心电图改变更不典型,NT-proBNP更高,超声示左右心室功能障碍更多,更需正性肌力/血管升压药。
- 入ICU率高于对照A(OR=3.22,95%CI 1.43–7.23)。
- 院内死亡率高于对照B(OR=7.75,95%CI 2.77–21.7)。
证据类型、等级与局限
- 证据类型:病例对照、回顾性、多中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者建议:COVID-19患者出现急性(心)肌心包炎时应快速识别,行超声心动图评估心肌心包炎症/功能障碍,必要时使用血管活性药物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To estimate incidence, risk factors, clinical characteristics and outcomes of acute (myo)pericarditis (AMP) in patients with COVID-19.
METHODS: Case-control, retrospective review, consecutive case inclusion performed in 62 Spanish EDs. All COVID-19 patients with AMP (cases) were compared in clinical characteristics and outcomes with COVID-19 without AMP (control group A) and non-COVID patients with AMP (control group B). We estimated unadjusted standardised incidence (SI, not adjusted by population's age/sex) of AMP in COVID-19 and non-COVID populations (per 100 000/year).
RESULTS: We identified 67 AMP in COVID-19 patients (SI=56.5, OR with respect to non-COVID patients=4.43, 95% CI=3.98 to 4.94). Remarkably, COVID-19 cases presented with chest pain less frequently than non-COVID patients and had less typical ECG changes, higher NT-proBNP (N-terminal prohormone of brain natriuretic peptide), more left and right ventricular dysfunction in echocardiography and more need of inotropic/vasopressor drugs. Admission to intensive care was higher than control group A (OR=3.22, 95% CI=1.43 to 7.23), and in-hospital mortality was higher than control group B (OR=7.75, 95% CI=2.77 to 21.7).
CONCLUSION: AMP is unusual as a form of COVID-19 presentation (about 1‰ cases), but SI is more than fourfold higher than non-COVID population, and it is less symptomatic, more severe and has higher in-hospital mortality; therefore, rapid recognition, echocardiographic assessment of myopericardial inflammation/dysfunction and treatment with vasoactive drugs when needed are recommended in AMP in patients with COVID-19.
参考来源
- Mirò Ò, Sabaté M, Jiménez S, et al. A case-control, multicentre study of consecutive patients with COVID-19 and acute (myo)pericarditis: incidence, risk factors, clinical characteristics and outcomes. Emerg Med J. 2022. PMID: 35304388. doi:10.1136/emermed-2020-210977
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。